[Resistant schizophrenia: what chemotherapy?].
Vanelle
J M
JM
Service hospitalo-universitaire de Santé mentale et de Thérapeutique, hôpital Sainte-Anne, Paris.
D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D008094:Lithium / Q000009:adverse effects / Q000627:therapeutic use; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014151:Anti-Anxiety Agents; D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D002220:Carbamazepine; D008094:Lithium; D011433:Propranolol; D003024:Clozapine
Schizophrénies résistantes: quelles chimiothérapies?